Janux Therapeutics Inc (JANX)
50.47
+3.97
(+8.54%)
USD |
NASDAQ |
Nov 22, 16:00
50.47
0.00 (0.00%)
After-Hours: 18:35
Janux Therapeutics Revenue (Quarterly): 0.439M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.439M |
| June 30, 2024 | 8.897M |
| March 31, 2024 | 1.252M |
| December 31, 2023 | 2.461M |
| September 30, 2023 | 2.517M |
| June 30, 2023 | 1.057M |
| March 31, 2023 | 2.048M |
| December 31, 2022 | 2.845M |
| Date | Value |
|---|---|
| September 30, 2022 | 1.813M |
| June 30, 2022 | 2.365M |
| March 31, 2022 | 1.589M |
| December 31, 2021 | 1.616M |
| September 30, 2021 | 1.159M |
| June 30, 2021 | 0.482M |
| March 31, 2021 | 0.38M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.38M
Minimum
Mar 2021
8.897M
Maximum
Jun 2024
2.061M
Average
1.616M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Dynavax Technologies Corp | 80.63M |
| Krystal Biotech Inc | 83.84M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.06M |
| Total Expenses (Quarterly) | 36.28M |
| EPS Diluted (Quarterly) | -0.51 |
| Enterprise Value | 1.782B |
| Profit Margin (Quarterly) | -6.39K% |
| Earnings Yield | -2.30% |
| Normalized Earnings Yield | -2.298 |